Identifying and reducing the risk of antipsychotic drug interactions

Progress in Neurology and Psychiatry

Volumn 16, Issue 2, 2012, Pages 20-24

  Bleakley, Stephen ^a  

^a Southern Health Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CODEINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUVOXAMINE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE;

CIGARETTE SMOKING; COFFEE; COMORBIDITY; CONSTIPATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; HUMAN; LOW DRUG DOSE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84860348382     PISSN: 13677543     EISSN: 1931227X     Source Type: Journal    
DOI: 10.1002/pnp.231     Document Type: Review

References (10)

1. Guedon-moreau L, Ducrocq D, Duc M-F, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: Analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003;59:689-95.
2. Baxter K. Stockley's Drug Interactions, 9th edn. London: Pharmaceutical Press, 2010.
3. Bazire S. Psychotropic Drug Directory 2012. Malta: Lloyd-Reinhold Communications LLP, 2012.
4. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58:871-85.
5. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogeomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286:2270-9.
6. De Leon J, Armstrong S, Cozza K. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75-85.
7. Roche Amplichip CYP450 test. Updated 2009 (assessed January 2012). Roche Diagnostics Ltd; available at www.roche.co.uk
8. Fleeman N, McLeod C, Bagust A, et al. The clinical effectiveness and cost effectiveness of testing for cytochrome P450 polymorphisma in patients with schizophrenia: a systematic review and economic evaluation. Health Technol Assess 2010;14(3).
9. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines, 10th edn. London: Informa Healthcare, 2009.
10. Lowe E, Ackman M. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 2010;44: 727-32.